{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nogapendekin alfa inbakicept (N-803)","tislelizumab"],["nogapendekin alfa inbakicept (N-803)"]],"indication":"immune checkpoint inhibitor-resistant stage IV NSCLC","name":"ResQ201A","nct_id":"NCT06745908","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=resq201a-nct06745908. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"3-week cycles. N803, Tislelizumab, and Docetaxel will be administered on Cycle 1 and 2. N803 and Tislelizumab will be administered on Cycle 3 and onward until end of study.","label":"Cohort A: Experimental Arm","type":"EXPERIMENTAL"},{"description":"The control arm treatment regimen will consist of repeated 3-week cycles with a ± 3-day window for each visit of Docetaxel 75 mg/m2 IV.","label":"Cohort A: Control Arm","type":"ACTIVE_COMPARATOR"},{"description":"3-week cycles. N803, prior failed checkpoint inhibitor, and Docetaxel will be administered on Cycle 1 and 2. N803 and prior failed checkpoint inhibitor will be administered on Cycle 3 and onward until end of study.","label":"Cohort B: Experimental Arm","type":"EXPERIMENTAL"},{"description":"The control arm treatment regimen will consist of repeated 3-week cycles with a ± 3-day window for each visit of Docetaxel 75 mg/m2 IV.","label":"Cohort B: Control Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-01","type":"ESTIMATED"},"conditions":["NSCLC Stage IV"],"enrollment":{"count":507,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"N-803","otherNames":[],"type":"DRUG"},{"name":"Tislelizumab","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Prior failed checkpoint inhibitor","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-02","lead_sponsor":"ImmunityBio, Inc.","official_title":"Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Compare Overall Survival between the experimental and control arms","timeFrame":"Approximately 12 months"}],"references":[],"start_date":{"date":"2025-10-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy","url":"https://clinicaltrials.gov/study/NCT06745908"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/resq201a-nct06745908"}